S626
Clinical – Head & neck
ESTRO 2026
Metro North Health, Queensland, Australia. 4 Caring Futures Institute, Flinders University, Adelaide, Australia. 5 Department of Oncology, McGill University, Montreal, Canada. 6 Department of Oncology, Princess Margaret Hospital, Hong Kong, Hong Kong. 7 Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada. 8 Department of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, USA Purpose/Objective: StrataXRT has demonstrated promise in reducing the incidence of severe acute radiation dermatitis (ARD) compared with standard of care (SoC) in randomized controlled trial involving patients with head and neck cancer undergoing radiotherapy (RT). Unlike barrier films, StrataXRT offers improved flexibility and adherence over complex anatomical contours, enhancing its practicality in clinical use. However, its comparatively high acquisition cost has raised concerns regarding its cost-effectiveness. This study used data from an Australian RCT to evaluate the cost- effectiveness of StrataXRT versus SoC for prevention and management of ARD, from Australian healthcare
impact on the overall cost-effectiveness conclusions. Conclusion: StrataXRT is a cost-effective option for preventing high-grade ARD in head and neck cancer patients receiving RT within the Australian healthcare system. Region-specific evaluations, incorporating ARD incidence and utility values, are essential to determine the cost-effectiveness of StrataXRT in other healthcare systems. References: 1. Chan RJ, Blades R, Jones L, Downer TR, Peet SC, Button E, Wyld D, McPhail S, Doolan M, Yates P. A single-blind, randomised controlled trial of StrataXRT® - A silicone-based film-forming gel dressing for prophylaxis and management of radiation dermatitis in patients with head and neck cancer. Radiother Oncol. 2019 Oct;139:72-78. doi: 10.1016/j.radonc.2019.07.014. Epub 2019 Aug 21. 2. Hsuan Chen Y, Kroesen M, Hoogeman M, Versteegh M, Uyl-de Groot C, Blommestein HM. Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study. Clin Transl Radiat Oncol. 2025 Jan
9;51:100913. doi: 10.1016/j.ctro.2025.100913. Keywords: Head and neck cancer, Radiation dermatitis
payers’ perspective. Material/Methods:
A decision tree model was developed to assess the cost-effectiveness of StrataXRT versus SoC (Sorbolene) in preventing ≥ Grade 3 ARD in head and neck cancer patients undergoing RT ( ≥ 50 Gy). Cost parameters in AUD, including StrataXRT acquisition, wound dressing, and nursing care, were based on data from a Brisbane cancer center.Quality-of-life utility values were extrapolated from a longitudinal study in the Netherlands on ARD in head and neck cancer patients receiving proton therapy. Incremental cost- effectiveness ratios (ICERs) were calculated as cost per quality-adjusted life-year (QALY) gained to compare StrataXRT with SoC, using a willingness-to-pay threshold of AUD 45,000. One-way sensitivity analyses were conducted to assess the robustness of the model findings to parameter uncertainties. Results: Utility values were set at 0.924 for ≥ Grade 3 ARD and 0.95 for <Grade 3 ARD. Base case analysis demonstrated that StrataXRT is cost-effective in preventing ≥ Grade 3 ARD compared to SoC, with an ICER of AUD 38,950 per QALY gained. When nursing cost was included, StrataXRT resulted in an improved ICER of AUD 31,710 per QALY gained compared to SoC.One-way sensitivity analysis revealed that the results were most sensitive to utility values and the incidence of ≥ Grade 3 ARD, emphasizing the crucial need for accurate estimation of clinical and utility inputs, particularly when adapting the model to other countries. On the other hand, variations in the costs of SoC, StrataXRT, and wound management had minimal
Digital Poster 3573 Development of a risk stratification model for distant metastasis in patients with nasopharyngeal carcinoma Liuling Wang, Zhaodong Fei, Chuanben Chen Radiation Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, China Purpose/Objective: Distant metastasis remains a challenging issue and is a major cause of treatment failure in nasopharyngeal carcinoma (NPC) patients. This study aims to develop a predictive risk stratification model for distant metastasis (DM) in NPC patients, identify corresponding risk factors, and provide a clinical decision-support nomogram. Material/Methods:
We retrospectively analyzed 7,045 NPC patients treated between Jan 1, 2012 and Jan 17, 2023. The
Made with FlippingBook - Share PDF online